Education
About Us
Working with TipRanks
Follow Us
Active Biotech AB (SE:ACTI)
:ACTI
ACTI Stock Chart & Stats
kr0.04
<kr0.01(1.97%)
At close: 4:00 PM EST
kr0.04
<kr0.01(1.97%)
Day’s Range― - ―
52-Week Rangekr0.04 - kr0.27
Previous CloseN/A
Volume903.68K
Average Volume (3M)4.56M
Market Cap
kr144.72M
Enterprise Valuekr2.63M
Total Cash (Recent Filing)kr65.10M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.68
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,636,067,100
10 Day Avg. Volume2,218,804
30 Day Avg. Volume4,558,826
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtThe company's near-zero debt position and falling leverage materially reduce interest obligations and refinancing pressure. This provides durable financial flexibility to fund R&D, tolerate clinical timelines, and negotiate partnerships without immediate debt servicing constraints, improving strategic optionality.
Improving Cash Burn And Operating LossesA multi-year trend of narrower operating losses and reduced cash burn indicates stronger cost discipline and operational efficiency. If sustained, this extends runway, lowers near-term financing reliance, and increases the probability that programs reach milestone events that can generate licensing revenue.
Out‑licensing / Partnering Business ModelA partnership-and-licensing model reduces capital intensity and commercialization risk versus owning product launches. It aligns incentives with larger partners for late‑stage development, allows milestone-driven cash inflows, and is a durable model for small biotechs to monetize science without large commercial infrastructure.
Bears Say
No Revenue Across 2021–2025The absence of product or recurring revenue over multiple years leaves the company dependent on unpredictable milestone payments or financing. This structurally increases funding risk, makes long-term planning more uncertain, and reduces resilience to trial setbacks or partnership delays.
Persistent Negative Operating Cash FlowSustained negative operating cash flow erodes cash reserves and necessitates periodic external funding. Even with improvements, ongoing cash burn increases dilution and financing execution risk, and constrains the company’s ability to independently advance multiple programs or respond to development setbacks.
Deep Negative Profitability And Volatile EquityPersistent net losses and deeply negative returns on equity undermine shareholder value and make long-term investor support harder to secure. Volatile equity levels signal frequent financing or write-downs, which can dilute incumbents and limit the firm's strategic freedom to invest in or partner programs.
Active Biotech AB News
ACTI FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was kr0.04 and its highest was kr0.27 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr144.72M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is May 07, 2026 which is in 64 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Feb 12, 2026. The company reported -kr0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.007.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 2,636,067,100 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in SE:ACTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―